In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Luis Antonio Flores-LópezLaboratorio de Biomoléculas y Salud Infantil, SECIHTI-Instituto Nacional de Pediatría, Mexico City 04530, Mexico.ORCID 0000-0002-2332-4361 Gabriela López-HerreraLaboratorio de Inmunodeficiencias Primarias, Instituto Nacional de Pediatría, Secretaría de Salud, Mexico City 04530, Mexico.ORCID 0000-0002-5498-6739 Yoalli Martínez-PérezEscuela de Medicina y Ciencias de la Salud, Tecnológico de Monterrey, Mexico City 14380, Mexico.
Elías Jaime Matadamas-OrtizLaboratorio de Investigación de Agro-Recursos y Metabolitos Secundarios, Universidad Autónoma Chapingo, Texcoco 56230, Mexico.
Saúl Gómez-ManzoLaboratorio de Bioquímica Genética, Instituto Nacional de Pediatría, Secretaría de Salud, Mexico City 04530, Mexico.ORCID 0000-0003-2095-9182 Gloria Hernández-AlcántaraDepartamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.ORCID 0000-0002-7029-6033 Angélica González-MacielLaboratorio Morfología Celular y Tisular, Instituto Nacional de Pediatría, Secretaría de Salud, Mexico City 04530, Mexico.ORCID 0000-0003-1909-9146 Rafael Reynoso-RoblesLaboratorio Morfología Celular y Tisular, Instituto Nacional de Pediatría, Secretaría de Salud, Mexico City 04530, Mexico.ORCID 0000-0001-8833-1151 Beatriz Hernández-OchoaLaboratorio de Investigación en Ciencias Ómicas y Epidemiología Microbiana, Hospital Infantil de México Federico Gómez, Secretaría de Salud, Mexico City 06720, Mexico.
Laura Chino-RíosPosgrado en Ciencias Biológicas (Maestría), Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.ORCID 0009-0005-8191-3833 Diego González-GómezLicenciatura en Bioquímica Diagnóstica, Facultad de Estudios Superiores Cuautitlán, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.
Leonardo Valente Arteaga-PadillaLicenciatura en Bioquímica Diagnóstica, Facultad de Estudios Superiores Cuautitlán, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.
Sergio Enríquez-FloresLaboratorio de Biomoléculas y Salud Infantil, Instituto Nacional de Pediatría, Secretaría de Salud, Mexico City 04530, Mexico.ORCID 0000-0003-2058-5707 Ignacio De la Mora-de la MoraLaboratorio de Biomoléculas y Salud Infantil, Instituto Nacional de Pediatría, Secretaría de Salud, Mexico City 04530, Mexico.ORCID 0000-0002-5654-8089 Funding
E022 Program, National Institute of Pediatrics, (Recursos Fiscales para la Investigación) 2022/067 (to L.A.F.-L.)National Institute of Pediatrics 2019/072, 2025/025 (to S.E.-F.)National Institute of Pediatrics; Recursos Fiscales para la Investigación 031/2025 (to I.M.-M.)Secretaría de Ciencia, Humanidades, Tecnología e Innovación (SECIHTI) CF-2023-1254 I-811 (to S.E.-F.)Secretaría de Ciencia, Humanidades, Tecnología e Innovación (SECIHTI), Ciencia de Frontera CF-2023-I-2755 (to L.A.F.-L.)
6 · The paper itselfAbstract
The emergence of clinical resistance to conventional antigiardials underscores the need for compounds with novel mechanisms of action. This study demonstrates that indirubin exerts antigiardial activity by targeting important metabolic enzymes in
Indexed as
Aldehyde ReductaseAntiprotozoal AgentsEnzyme InhibitorsGiardia lambliaIndolesTriose-Phosphate IsomeraseGlycation End Products, AdvancedHumansPyruvaldehydeTrophozoitesAldehyde ReductaseAntiprotozoal AgentsEnzyme InhibitorsGlycation End Products, AdvancedindirubinIndolesPyruvaldehydeTriose-Phosphate Isomerasecarbonyl stressdimethylsulfoxidedual effectindirubinmetabolic inhibitionmethylglyoxal
Identifiers
PMID42196151
PMCPMC13206313
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390